Company intelligence / Profile preview
Leucid Bio
London, England, United Kingdomleucid.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Currently enrolling patients in Phase 1 AERIAL trial for LEU011, with proof-of-concept data expected by year-end 2025
- Therapeutic areas
- Oncology
- Modalities
- CAR-T cell therapy
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Beyond the preview
Go deeper on Leucid Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Leucid Bio.